Aerie Pharmaceuticals — Investor Presentation (November 2018)
27 slides from Aerie Pharmaceuticals's investor presentation, Nov 13, 2018
Slide 1: Company Overview Investor Presentation
Exhibit 99.1 Company Overview Investor Presentation November 2018
Slide 2: Important Information
Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety
Slide 3: Aerie Overview
Aerie Overview Aerie IOP–Reducing Products (IP 2030+) • Rhopressa® (netarsudil ophthalmic solution) 0.02% • Successfully launched in U.S. April 30, 2018 • Rocklatan™ (netarsudil / latanoprost ophthalmic solution) 0.02% / 0.005% • U.S. NDA accepted, PDUFA set for March 14, 2019 • Globalization Plan U
Slide 4: Rhopressa: Market Perspective
Rhopressa ®: Market Perspective CAI Lumigan 8% 10% 2017 U.S. Glaucoma Market Travatan 7% AA 10% Fixed Latanoprost - ~$3B Market, 37M TRx, 61M bottles Combo 37% - Half of volume first-line (PGAs) 15% - Half of volume 2-3X/Day Adjuncts BB 13% Rhopressa®: HCP’s Positioning as Concomitant Therapy - New
Slide 5: Rhopressa Formulary Coverage Increasing
Rhopressa ® Formulary Coverage Increasing As of 10/01/18: ~85% of Commercial Lives Covered ~40% Medicare Part D Lives Covered Preferred Tier Non-preferred Tier 45% 55% 40% 40% 25% 12% 9/01/18 10/01/18 9/01/18 10/01/18 ------------Commercial------------- -----------Medicare Part D--------- For Invest
Slide 6: Rhopressa U.S. Launch Update
Rhopressa ® U.S. Launch Update Weekly IQVIA Total Rx’s and Extended Units: Week 30: 11/2/18 Week Ending 11/9/18: 5,850 Wholesaler Shipments to Pharmacies = 7,263 4,726 *Actual bottles dispensed exceed TRx’s due to extended supply plans (e.g., 90 days’ supply) Rhopressa® has not been approved by any
Slide 7: Rhopressa U.S. Launch Update
Rhopressa ® U.S. Launch Update Strong Net Sales and Volume Growth: $122 net sales per unit $136 net sales per unit Rhopressa® has not been approved by any regulatory authority other than the FDA. For Investor Use 7
Slide 8: Early Rhopressa Feedback
Early Rhopressa ® Feedback Physician Examples: End-stage glaucoma patient at brink of needing surgery. Patient on maximal medical therapy (PGA/Combo/CAI) with IOP of 18 mmHg. Added Rhopressa® and IOP dropped to 13 mmHg, avoiding surgery. Patient on maximal drug therapy and inadequately controlled at
Slide 9: Active Engagement at Key Conferences
Active Engagement at Key Conferences American Glaucoma Society Association of Research American Society of Cataract and (AGS) in Vision and Refractive Surgeons (ASCRS) March 2018 Ophthalmology (ARVO) April 2018 April 2018 European Glaucoma Society (EGS) Florence, May 2018 European Society of Catarac
Slide 10: Rocklatan Combination Product Candidate
RocklatanTM Combination Product Candidate Rocklatan TM (netarsudil / latanoprost ophthalmic solution)0.02% / 0.005% Positioning as First Line Therapy: • Benefits of Rhopressa® while also targeting the secondarydrain • Achieved statistical superiority to market-leading latanoprost - At each of nine t
Slide 11: Rocklatan Efficacy and Safety
RocklatanTM Efficacy and Safety Efficacy: • Rocklatan TM demonstrated statistical superiority over its components (market- leading PGA latanoprost and Rhopressa®) in Mercury 1 and 2 Phase 3 trials, at all measured time points • Consistent incremental IOP-reduction over latanoprost and Rhopressa® in
Slide 12: Rocklatan Phase 3 Month 12 Responder Analysis
Rocklatan TM Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patientswith IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 For Investor Use 12
Slide 13: Rocklatan Next Steps
RocklatanTM Next Steps • Rocklatan TM NDA submission accepted, with March 14, 2019 PDUFA • Current U.S. sales force will be trained on Rocklatan TM in advance of PDUFA • Commercial formulary access expected to be finalized post-approval • Medicare Part D formulary submission to payers expected in Ap
Slide 14: Expanding Aerie Franchise: Europe and Japan
Expanding Aerie Franchise: Europe and Japan • Europe (2017 Europe “Big 5” Glaucoma Market: 91M units per year, 1.5X U.S. units) • MAA accepted for Rhokiinsa® (Rhopressa®) in October 2018, expect 12-month review • Mercury 3: 6-month safety and 90-day efficacy registration trial comparing RocklatanTM
Slide 15: Europe Glaucoma Market
Europe Glaucoma Market: Aerie Expects to Commercialize on Its Own (if approved) “Big 5” Europe Glaucoma Market – 2017 $1.0B; 91M TRx*, Market Share in TRx Non-PGA Market (47%) PGA Market (53%) Others Bimatoprost 2 - 4 Times Daily CAI Once Daily 2% Travoprost 10% 13% 5% AA 4% Latanoprost 19% 17% Non-
Slide 16: Japan Glaucoma Market
Japan Glaucoma Market: Aerie Expects to Partner for Commercialization (if approved) Japan Glaucoma Market – 2017 $0.8B; 54M TRx*, Market Share in TRx Non-PGA Market (48%) PGA Market (52%) 2 - 4 Times Daily 2% Once Daily 4% 6% (Unoprostone is bid) 9% 5% 12% 19% 13% 8% 9% 11% PGA: Prostaglandin Analog
Slide 17: Advancing the Pipeline
Advancing the Pipeline • Rhopressa® ResearchTargets • 24-hour IOP reduction • Potential in normal tension glaucoma • Aqueous humor dynamics (trabecular outflow, episcleral venous pressure) • Pseudoexfoliative glaucoma • Corneal healing • Retina Program Opportunities: AR-1105 (dexamethasone steroid)
Slide 18: Retinal Eye Diseases – Aerie's Next Chapter
Retinal Eye Diseases – Aerie’s Next Chapter The retinal disease market is twice that of glaucoma with $4.9 billion in the U.S. and $9 billion worldwide per IQVIA Current treatments lose efficacy over time, some have very serious side effects and there are limited surgical options The majority of cur
Slide 19: 2017 U.S. Retinal Disease Market
2017 U.S. Retinal Disease Market 2017 Sales: $5.3B Unit Sales: 6.8M steroids, others, steroids, others, $0.15 $0.02 0.23 0.11 Lucentis, 0.86 Lucentis, $1.44 Eylea, 2.61 Eylea, $3.70 Avastin, $0.02 Avastin, 3.03 Sources: Mix of public information, IQVIA and estimates For Investor Use 19
Slide 20: AR-1105: Dexamethasone Implant
AR-1105: Dexamethasone Implant • Target indications • Macular edema due to diabetic retinopathy (DME) • Macular edema due to retinal vein occlusion (RVO) • Unmet need • First line anti-VEGF agents often not sufficient even with monthly intravitreal (IVT) injections • Current second-line steroid trea
Slide 21: AR-13503: First-in-Class ROCK/PKC Inhibitor for Wet AMD and DME
AR-13503: A First-in-Class ROCK/PKC Inhibitor for the Treatment of Wet AMD and DME • Active metabolite of netarsudil • Potential to improve outcomes by targeting multiple disease processes • Monotherapy shows strong efficacy in preclinical models • Effective as adjunct to anti-VEGF therapy in precli
Slide 22: Preclinical AR-13503 Provides Efficacy Similar to Eylea in PDR Model
Preclinical AR-13503 Provides Efficacy Similar to Eylea® in a Proliferative Diabetic Retinopathy Model Oxygen-induced retinopathy (OIR) mouse model - PDR Vehicle 1.25 mg/kg AR-13503 1 mg/kg Eylea (n=14) (n=16) (n=14) Administration: Intraperitoneal QD Data on File For more information on Eylea® plea
Slide 23: AR-13503 Synergistic to Eylea in Mouse Model of PDR
AR-13503 Synergistic to Eylea ® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR Neovascular Area (+SEM) * : p<0.01 *** : p<0.0001 Administration: Intraperitoneal QD Data on File Sub-optimal dose levels selected in the study to provide less than
Slide 24: DSM Collaboration – Implant Delivery Technology
DSM Collaboration – Implant Delivery Technology • Bio-erodible implant technology • Aerie now has a worldwide exclusive license for all ophthalmic indications • Broad sustained release platform for treatment of Wet AMD and DME, as well as glaucoma • Promising results from ongoing feasibility study •
Slide 25: PRINT Technology for Ophthalmology
PRINT® Technology for Ophthalmology Micropatterned Mold formation Mold Filling Particle Array Template (e.g. drug/polymer) PRINT= Particle Replication In Non-wetting Templates Aerie has the rights to use this technology for ophthalmic applications Proprietary technology capable of creating precisely
Slide 26: Evaluating Aerie's 3,500+ Owned Molecules
Evaluating Aerie’s 3,500+ Owned Molecules • Commencing screening for additional indications beyond ophthalmology • ROCK inhibition should have potential in: • Pulmonary health, ROCK including pulmonary fibrosis and bronchial asthma • Dermatology indications • Cancer Aerie molecules inhibit both ROCK
Slide 27: Summary
Summary • Key Priorities • Rhopressa®: Successful launch execution TM • Rocklatan : U.S. PDUFA set for March 14, 2019 • Globalization Strategy • Europe/Japan clinical path and commercialization strategy • Ireland Manufacturing Facility • Research Initiatives • Rhopressa® 24-hour IOP reduction, norma
Aerie Pharmaceuticals — Investor Presentation (November 2018) on 6ix